David Teachey Laboratory

Ongoing Research

Clinical Use of the mTOR Pathway Inhibitor Sirolimus (rapamycin) to Treat Children with Autoimmune Lymphoproliferative Syndrome (ALPS)

Clinical trials are underway at the Center for Childhood Cancer Research to evaluate the use of sirolimus as a treatment for refractory pediatric autoimmune diseases.

Toxicity Management for Pediatric Acute Lymphoblastic leukemia (ALL) Patients Treated with Chimeric Antigen Receptor (CAR) T-cells

Clinical studies conducted by physician scientists at the CCCR have demonstrated that administration of tocilizumab — a recombinant humanized anti-IL6 receptor monoclonal antibody that interferes with secretion of the cytokine IL6 — can be an effective treatment for pediatric patients who develop cytokine release syndrome (CRS) after CART or BiTE therapy.